Bent R.

GAIASO Theranostics exists to change outcomes in women’s cancers by developing more effective therapies, ultimately delivering longer, healthier and more dignified lives. We’re closing the gender gap in oncology by advancing a new generation of radiotheranostics. Built on the Affilin® protein-engineering platform and developed with our partners at PreMIT Pty Ltd, our programs combine precise tumour targeting, optimised biodistribution, and rational combinations to enhance efficacy. Our urgent mission is to accelerate life-saving options for more women, worldwide.

Optigo Biotherapeutics is an innovative pre-clinical stage biotherapeutics company working to develop cutting-edge treatments to address vision loss from chronic ophthalmic diseases.

Join ProGlove – Build technology that works for people At ProGlove, we develop industrial wearable solutions that connect people and technology on the shopfloor. From engineering & product to operations, sales, marketing, people experience and finance, our teams work together to deliver solutions that make a real difference. We are an international company with offices in Munich, Belgrade, Chicago, and Coventry, collaborating closely across locations. Different perspectives, backgrounds, and experiences are part of how we succeed together. We value ownership, clarity, and collaboration – and we support you in growing your way, while contributing to something meaningful. 👉 Apply now and become part of ProGlove: https://proglove.com/careers/#open-positions

KONUX is a leading German AI scale-up, transforming railway operations for a sustainable future. We combine Machine Learning and industrial IoT to make railway the mobility choice of tomorrow by increasing capacity, reliability, and cost-efficiency. Since its founding in 2014, KONUX has expanded to numerous countries in Europe and Asia, and was selected by the World Economic Forum (WEF) as one of the world’s 30 most innovative start-ups and scale-ups worldwide. Do you want to join our team and help us take IoT where it really makes a difference? Do you love to take ownership and go the extra mile to ensure our customers’ success? Are you ready to work in an environment that believes in open feedback, constant growth, and a strong team culture? KONUX might be the place for you! Check out konux.com/career or contact us at career@konux.com.

Your Real-Time Database for Analytics, Search, and AI.

PASSION FOR PRECISION. ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. For more information please visit: www.itm-radiopharma.com. Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines

GAIASO Theranostics exists to change outcomes in women’s cancers by developing more effective therapies, ultimately delivering longer, healthier and more dignified lives. We’re closing the gender gap in oncology by advancing a new generation of radiotheranostics. Built on the Affilin® protein-engineering platform and developed with our partners at PreMIT Pty Ltd, our programs combine precise tumour targeting, optimised biodistribution, and rational combinations to enhance efficacy. Our urgent mission is to accelerate life-saving options for more women, worldwide.

Munich Precision Oncology’s (MPO) objective is to develop and establish dedicated precision oncology centres globally in partnership with leading companies and academic institutions. The centers will provide the highest standard and cutting-edge technology in precision oncology and theranostic patient care.

We focus on investing in entrepreneurial businesses with a bold, visionary purpose—those committed to creating transformational solutions with a significant positive impact on society.

Optigo Biotherapeutics is an innovative pre-clinical stage biotherapeutics company working to develop cutting-edge treatments to address vision loss from chronic ophthalmic diseases.

Capmont is an entrepreneurial private capital investment manager. We concentrate on Europe with a particular focus on the DACH region (Germany, Austria, Switzerland), Northern Italy and Poland. Capmont operates four offices in Europe and two investment strategies: Private Equity and Technology With strong roots in our focus regions and deep integration into European and global networks, Capmont excels in value creation and field-level operational support. This expertise combined with proprietary access to unique investment opportunities, a highly selective approach and superior execution skills, results in a leading risk-return profile through majority or protected minority stakes. Feel free to contact us as an entrepreneur, investor or seller.